Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline

Movement Disorders

Volumn 21, Issue 10, 2006, Pages 1716-1721

  deMarcaida, J Antonelle ^a   Schwid, Steven R ^a,b   White, William B ^b   Blindauer, Karen ^c   Fahn, Stanley ^d   Kieburtz, Karl ^a   Stern, Matthew ^e   Shoulson, Ira ^a   Deeley, Cheryl ^f   Pool, James ^g   Taylor, Addison ^g   Anderson, Catherine ^g   Forster, Alan ^h   Colcher, Amy ⁱ   Beim, Jay ^j   Card, Sharron ^j   Turpin, Denyse ^k   Roberts, Ted ^l   Perry, Gareth ^m   Esterbrooks, Dennis ⁿ   Mohiuddin, Syed ⁿ   Jenkins, Steven ^o   Marso, Jean ^p   Siderowf, Andrew ⁱ   Matthews, Mary ⁱ   Mooss, Aryon ⁿ   Rasmussen, Lois ⁿ   Tietjen, Gretchen ^q   Korsnack, Andrea ^q   Kurlan, Roger ^f   Hickey, Charlyne ^f   Saint Hilaire, Marie ^k   Derksen, Carol ^l   Maddux, Brain ^r   Brown, John ^s   Grimes, David ^h   Evatt, Marian ^t   Ingram, Carol ^t   Ahmed, Anwar ^u   Kolb, Ruth ^u   Belber, Sheila ^v   more..

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d NEUROLOGICAL INSTITUTE   (United States)

^e Penn Neurological Institute   (United States)

^f UNIVERSITY OF ROCHESTER   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF OTTAWA   (Canada)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j Saskatoon Health District Board   (Canada)

^k BOSTON UNIVERSITY   (United States)

^l UNIVERSITY OF ALBERTA   (Canada)

^m UNIVERSITY OF MINNESOTA   (United States)

ⁿ CREIGHTON UNIVERSITY   (United States)

^o Parkinson's and Movement Disorder Institute   (United States)

^p UNIVERSITY OF COLORADO   (United States)

^q MEDICAL COLLEGE OF OHIO   (United States)

^r UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^s LONDON HEALTH SCIENCES CENTRE   (Canada)

^t EMORY UNIVERSITY   (United States)

^u LERNER RESEARCH INSTITUTE   (United States)

^v UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

more..

Author keywords

Monoamine oxidase inhibitor; Parkinson's disease; Pressor response; Rasagiline; Tolerability; Tyramine

Indexed keywords

AMANTADINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; RASAGILINE; SEROTONIN UPTAKE INHIBITOR; TYRAMINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOOD DRUG INTERACTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DIET; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; AGED; ANTIPARKINSON AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOOD-DRUG INTERACTIONS; HEART RATE; HUMANS; INDANS; LEVODOPA; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; RISK FACTORS; TYRAMINE;

EID: 33750296512     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21048     Document Type: Article

References (20)

1. Blackwell B. Hypertensive crisis due to monoamine oxidase inhibitors. Lancet 1963;2:849-851.
2. Marley E, Blackwell B. Interactions of monoamine oxidase inhibitors, amines and foodstuffs. In: Garattini S, Goldin A, Hawking F, Kopin I, editors. Advances in pharmacology and chemotherapy. New York: Academic; 1970. p 185-239.
3. Varga E, Tringer L. Clinical trial of a new type promptly acting psychoenergic agent (phenylisopropyl methyl-porpinyl-HC1, E-250). Acta Med Acad Shi Hung 1967;23:189-295.
4. Lees AJ, Shaw KM, Hohost L, et al. Deprenyl in Parkinson's disease. Lancet 1977;11:791-795.
5. Birkmayer W, Riederer P, Youdirn MBH. (-) deprenyl in the treatment of Parkinson's disease. Clin Neuropharmacol 1982;5: 195-230.
6. Stern GM, Lees AJ, Sandler M. Recent observations on the clinical pharmacology of (-) deprenyl. J Neural Transm 1978;43:254-251.
7. Pickar D, Cohen RM, Jimmerson DC, Murphy DL. Tyramine infusions and selective monoamine oxidase inhibitor treatment: changes in pressor sensitivity. Psychopharmacology 1981;74: 4-7.
8. Frankel JP, Kempster PA, Stibe CMH, et al. A double blind controlled study of high dose 1-deprenyl in the treatment of Parkinson's disease. Clin Neuropharmacol 1989;12:448-451.
9. McGrath PJ, Stewart JW, Quitkin FM. Possible 1-deprenyl induced hypertensive reaction. J Clin Psychopharmacol 1989;9:310-311.
10. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 2002;59:1937-1943.
11. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-248.
12. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO study): a randomized, double-blind, parallel-group trial. Lancet 2005;365:947-954.
13. Leon LS, Abrams WB, Markowitz M, Meisner EC. The use of pressor sensitivity tests for detection of drugs with sympathetic nervous system activity. J Clin Pharmacol 1969;9:399-407.
14. Bieck PR, Antonin KH. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol 1988;8:237-245.
15. Weinstock M, Gorodetsky E, Wang RH, Gross A, Weinreb O, Youdim MB. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits. Neuropharmacology 2002;43:999-1005.
16. Grind M, Siwers B, Graffner C, et al. Pressor response of oral tyramine in healthy men given amiflamine and placebo. Clin Pharmacol Ther 1986;40:155-160.
17. Bianchetti MG, Minder I, Beretta-Piccoli C, Meier A, Weidmann P. Effects of tyramine on blood pressure and plasma catecholamines in normal and hypertensive subjects. Klin Wochenschr 1982;60:465-470.
18. Arias-Vera JR, Mansoor GA, White WB. Abnormalities in blood pressure regulation in a patient with Parkinson's disease. Am J Hypertens 2003;16:612-613.
19. Plaschke M, Trenkwalder P, Dahlheim H, et al. Twenty-four hour blood pressure profile and blood pressure responses to head-up tilt tests in Parkinson's disease and multiple system atrophy. J Hypertens 1998;16:1433-1441.
20. Berlin I, Zimmer R, Cournot A, Payan C, Pedarriosse AM, Puech AJ. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol 1989;46: 344-3 51.